Literature DB >> 28384870

Significant Haematogone Proliferation Mimicking Relapse in Acute Lymphoblastic Leukaemia on Therapy.

Smeeta Gajendra1, Ruchira Misra2, Pranav Dorwal1, Rashi Sharma3, Ritesh Sachdev4.   

Abstract

Haematogones are benign B lymphoid precursors which may mimic neoplastic lymphoblasts and pose diagnostic difficulty especially when the percentage of haematogones exceeds 10% in the bone marrow. Flow cytometric analysis with combination of CD19/CD10/CD20/CD34/CD38/CD58 can be used to differentiate the two depending upon the difference in the fluorescence intensity between blasts and haematogones. We hereby present a case of Common Acute Lymphoblastic Leukaemia Associated Antigen (CALLA) positive Acute Lymphoblastic Leukaemia (ALL), in which patient presented with haematogone proliferation in bone marrow after 6 months of chemotherapy mimicking relapse. The distinction was made on flow cytometric immunophenotyping by using optimal antibody combination. Distinction of benign haematogones from neoplastic lymphoblasts is essential for disease management in cases of post chemotherapy or post marrow transplant, especially in patients of ALL. Flow cytometric immunophenotyping is reliable to distinguish haematogones from residual lymphoblasts in almost all cases when optimal antibody combinations are used.

Entities:  

Keywords:  Benign B lymphoid precursors; Flow cytometry; Minimal Residual Disease

Year:  2017        PMID: 28384870      PMCID: PMC5376839          DOI: 10.7860/JCDR/2017/23650.9190

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  8 in total

1.  Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.

Authors:  P Lúcio; A Parreira; M W van den Beemd; E G van Lochem; E R van Wering; E Baars; A Porwit-MacDonald; E Bjorklund; G Gaipa; A Biondi; A Orfao; G Janossy; J J van Dongen; J F San Miguel
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

Review 2.  Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry.

Authors:  Robert W McKenna; Sheryl L Asplund; Steven H Kroft
Journal:  Leuk Lymphoma       Date:  2004-02

3.  CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.

Authors:  Ronald V Lee; Raul C Braylan; Lisa M Rimsza
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

4.  The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?

Authors:  Ł Sędek; J Bulsa; A Sonsala; M Twardoch; M Wieczorek; I Malinowska; K Derwich; M Niedźwiecki; G Sobol-Milejska; J R Kowalczyk; B Mazur; T Szczepański
Journal:  Cytometry B Clin Cytom       Date:  2014-05-21       Impact factor: 3.058

5.  Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.

Authors:  Takahiro Shima; Toshihiro Miyamoto; Yoshikane Kikushige; Yasuo Mori; Kenjiro Kamezaki; Ken Takase; Hideho Henzan; Akihiko Numata; Yoshikiyo Ito; Katsuto Takenaka; Hiromi Iwasaki; Tomohiko Kamimura; Tetsuya Eto; Koji Nagafuji; Takanori Teshima; Koji Kato; Koichi Akashi
Journal:  Blood       Date:  2012-12-11       Impact factor: 22.113

6.  Immunophenotypic analysis of bone marrow B lymphocyte precursors (hématogones) by flow cytometry.

Authors:  N Braham Jmili; S Nsaibia; M C Jacob; H Omri; M A Laatiri; S Yacoub; Y Braham; M Aouni; M Kortas
Journal:  Clin Lab Sci       Date:  2009

7.  Increased hematogones in an infant with bicytopenia and leucocytosis:a case report.

Authors:  Kiran Agarwal; Meenu Aggarwal; Vikas Kumar Aggarwal; Meenu Pujani; Manupriya Nain
Journal:  Cases J       Date:  2010-03-04

Review 8.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.